Background: Alzheimer's disease is a neurodegenerative disease, characterized by progressive decline in memory and cognitive functions, that results from loss of neurons in the brain. Amyloid beta (Aβ) protein and oxidative stress are major contributors to Alzheimer's disease, therefore, protecting neuronal cells against Aβ-induced toxicity and oxidative stress might form an effective approach for treatment of this disease. 3,5,4′-trihydroxy-6,7,3′-trimethoxyflavone (TTF) is a flavonoid we have purified from the plant Achillea fragrantissima; and the present study examined, for the first time, the effects of this compound on Aβ-toxicity to neuronal cells.
Background
Alzheimer's disease (AD), the most common form of dementia in adults, is characterized by widespread loss of neurons in the brain, which results in progressive memory loss and cognitive decline. AD is characterized by intraneuronal neurofibrillary tangles (aggregates of cytoskeletal hyperphosphorylated Tau protein) and extraneuronal senile plaques, formed mainly by aggregated amyloid beta (Aβ) peptides [1] . Aβ is a 39-to 43-amino acid peptide derived from the cleavage of amyloid precursor protein (APP), and it is involved in the pathogenesis of AD through several different mechanisms, including oxidative stress, microglial activation, neuronal dysfunction, and neuronal cell death [2, 3] . Thus, protecting neuronal cells against Aβ-induced cytotoxicity might form an effective approach to therapeutic treatment of Alzheimer's disease.
An increasing body of evidence shows the therapeutic potential of phytochemicals against various diseases, including AD [4, 5] . Flavonoids are phytochemicals that exhibit a broad range of biological functions, including anti-inflammatory, antioxidative and neuroprotective activities [6] [7] [8] [9] [10] [11] . In light of these activities, they seem to be promising candidates for development as drugs for treatment of neurodegenerative diseases [8, 12, 13] .
In a previous study, we have shown that 3,5,4′-trihydroxy-6,7,3′-trimethoxyflavone (TTF), a flavonoid that we have isolated from Achillea fragrantissima, prevented the hydrogen peroxide (H 2 O 2 )-induced death of astrocytes, and inhibited the phosphorylation of cell-signaling proteins that belong to the mitogen-activated protein kinase (MAPK) family [14] . TTF also scavenges free radicals and mitigates intracellular accumulation of ROS following treatment of these cells with H 2 O 2 or with the peroxyl radicals-generating molecule 2,2′-azobis(amidinopropane) (ABAP) [14] ; it is characterized by a relatively low polarity and low molecular weight of 360.3, therefore it might cross the blood-brain barrier and could be used for further investigations in cellular and animal models of AD.
In the present study, we aimed to determine whether TTF could counteract Aβ toxicity in N2a neuroblastoma cells, and to elucidate the molecular mechanisms involved.
Methods

Chemicals and reagents
Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] , crystal violet, and 2′,7′-dichlorofluorescein diacetate (DCF-DA) were purchased from Sigma Chemical Co. (St Louis, MO, USA); Dulbecco's modified Eagle's medium (DMEM) and Opti-MEM were purchased from Gibco (Paisley, UK); glutamine, antibiotics (10,000 IU/ mL penicillin and 10,000 μg/mL streptomycin), fetal bovine serum (FBS) and trypin-EDTA were purchased from Biological Industries (Beit Haemek, Israel); dimethyl sulfoxide (DMSO) was obtained from Applichem (Darmstadt, Germany).
Plant material
The aerial parts of A. fragrantissima were collected in the Arava Valley, and the voucher specimens have been kept and authenticated as part of the Arava Rift Valley Plant Collection under accession code AVPC0040.
Extraction and isolation
Isolation of TTF was carried out as previously described [14] . Briefly: the sun-dried A. fragrantissima plant was homogenized and extracted with ethyl acetate twice and with ethyl acetate:methanol (9:1) once. The organic extracts were combined and evaporated. The latter residue was chromatographed on a Sephadex LH-20 column that was eluted with methanol: CH 2 Cl 2 (1:1). A fraction yielded by the Sephadex LH-20 column, which was monitored by thin layer chromatography (TLC) and 1 H-nuclear magnetic resonance (NMR) and that protected astrocytes from H 2 O 2 -induced cell death, was further purified by repeated chromatography over silica gel, with hexane that contained increasing proportions of ethyl acetate used as eluent. The active compound was afforded by elution with 50% ethyl acetate in hexane.
Treatment of neuronal cells
The original medium was aspirated from the cells and replaced with fresh medium. Fresh dilutions of TTF, first in DMSO and then in the growth medium, were prepared from stock solution just prior to each experiment, and were used immediately. The final concentration of DMSO in the medium was 0.2%. The Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] peptide was dissolved in DDW and incubated at 37°C for 48 h. Fresh dilutions of Aβ in the growth medium were prepared just prior to each experiment and were used immediately. Each treatment was performed in replicates.
Determination of cytotoxicity and cell viability
Cytotoxicity -N2a cells were grown in a medium containing 43% DMEM (high glucose), 50% Opti-MEM, 5% FBS, 2 mM glutamine, penicillin at 100 U/mL, and streptomycin at 100 μg/mL. The cells were re-plated in 96-well plates at a density of 5 × 10 3 cells/well, in a similar medium; Aβ and/or TTF were added concomitantly 24 h later, and cytotoxicity was determined 20 h later with a commercial colorimetric assay (Roche Applied Science, Germany) based on the measurement of lactate dehydrogenase (LDH) activity released into the incubation medium from the cytosol of damaged cells. The absorbance was measured at 492 nm in a Synergy2 multi-detection microplate reader (BioTek Instruments, Inc., Winooski, VT, USA). The percentage of cytotoxicity was calculated according to:
in which the term "A Triton-x treated cells " is the maximum releasable LDH from the cells.
Cell viability -N2a cells were grown and treated as in the cytotoxicity assay, except that replating was at a density of 5 × 10 3 cells/well. Cell viability was determined by a modification of the crystal violet assay [15] , as follows. At the end of their treatments the cells were fixed with 150 μL of 5% (v/v) formaldehyde in PBS for 15 min at room temperature. The plates were washed by immersion in deionized water, dried and stained for 15 min with 150 μL of a 1% crystal violet solution. Following aspiration of the crystal violet solution the plates were washed with deionized water and dried, and the bound dye was solubilized with 150 μL of 33% aqueous solution of glacial acetic acid. The optical density was measured at 540 nm, by comparison with a 690-nm reference filter, in a Synergy2 multi-detection microplate reader (BioTek Instruments, Inc., Winooski, VT, USA).
Evaluation of intracellular ROS levels
Intracellular ROS levels were detected by using the nonfluorescent cell-permeating compound, 2′,7′-dichlorofluorescein diacetate (DCF-DA). The N2a cells were plated onto 96-well plates at 10,000 cells per 0.2-mL well, in 43% DMEM (high glucose), 50% Opti-MEM, 1% FBS, 2 mM glutamine, penicillin at 100 U/mL, and streptomycin at 100 mg/mL. After 24 h the cells were treated with 20 μM DCF-DA for 30 min at 37°C. Following incubation with DCF-DA, the cultures were rinsed twice with PBS, which was then replaced with fresh medium. The. ROS levels at time zero were evaluated according to fluorescence in a Synergy2 multidetection microplate reader (BioTek Instruments, Inc., Winooski, VT, USA) with excitation at 485 nm and emission at 520 nm. The cells were then treated with TTF and Aβ, and the ROS levels were measured at the indicated time points.
The percentage of ROS levels was calculated according to:
in which F is the fluorescence.
Enzyme-linked immunosorbent assays (ELISA) for total and phosphoSAPK/JNK, and total and phosphoERK (phospho-p44/42 MAPK) N2a cells were treated with TTF concomitantly with addition of Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . The cells were lysed after 40 or 30 min, for SAPK/JNK or ERK 1/2, respectively, in lysis buffer that was part of the PathScan Sandwich ELISA kit (Cell Signaling Technology, Danvers, MA, USA) according to the manufacturer's protocol. Protein concentrations in cell lysates were determined with Bradford reagent (Bio-Rad, Hercules, CA, USA), and equal amounts of proteins were subjected to ELISA. To measure the amounts of total and of phosphoSAPK/JNK in cell lysates of the N2a cells, ELISA was performed according to the manufacturer's protocols with the PathScan total SAPK/JNK sandwich ELISA kit and the PathScan phosphoSAPK/JNK (Thr183/Tyr185) sandwich ELISA kit, respectively (both kits from Cell Signaling Technology, Danvers, MA, USA). To measure the amounts of total and phosphoERK 1/2, i.e., phospho-p44/42 MAPK, in cell lysates, ELISA was performed according to the manufacturer's protocol with Cell Signaling Technology's PathScan total p44/42 MAPK (ERK 1/2) sandwich ELISA kit and the PathScan phospho-p44/42 MAPK (Thr202/Tyr204) sandwich ELISA kit, respectively. The optical density was measured at 450 nm with a Synergy2 multi-detection microplate reader (BioTek Instruments, Inc., Winooski, VT, USA).
Statistical analysis
The results were subjected to one-way ANOVA followed by Tukey-Kramer multiple comparison tests, by means of Graph Pad InStat 3 for Windows (GraphPad Software, San Diego, CA, USA).
Results
Protective effect of TTF against Aβ 25-35 -induced neuronal cell death Phytochemicals that can protect neuronal cells against Aβ toxicity and oxidative stress may assist in coping with Alzheimer's disease. In order to assess the ability of TTF (The structure of TTF is presented in Fig. 1 ) to counteract Aβ toxicity in N2a neuroblastoma cells, we have used the Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] peptide, which represents the neurotoxic fragments of Aβ 1-40 and Aβ , and is used in cell models to mimic their toxicity. Exposure of neuronal cells to Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] resulted in their death after 20 h, as reflected in a fivefold increase in the LDH assay (Fig. 2a) , and a 55% reduction in the crystal violet assay (Fig. 2b) . To assess the ability of TTF to protect neuronal cells against Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] , and to determine the optimal concentrations of TTF required to induce a protective effect, cells were treated with Aβ 25-35 at 25 μM and with various concentrations of TTF. Cytotoxicity and viability were determined after 20 h by means of the LDH assay (Fig. 2c) and the crystal violet assay (Fig. 2d) , respectively. Our results show that TTF exhibited a protective effect against Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] -induced cell death, with maximal efficacy (96% protection) at a concentration of 140 nM (Fig. 2c, d ). It should be noted that at all concentrations tested, up to 700 nM, the crystal violet assay did not show TTF alone to be cytotoxic to neuronal cells (Fig. 2e) .
Inhibitory effect of TTF on Aβ 25-35 -induced generation of ROS
The role of free radicals in AD has been reported in many studies [16] . Moreover, it has been shown that Aβ induced generation of reactive oxygen species (ROS), leading to neuronal death [3] . To investigate the effect of TTF on ROS levels, which are elevated in response to Aβ treatment, the levels of intracellular ROS were determined. Treatment of cells with Aβ 25-35 for 20 h resulted in a twofold increase in intracellular ROS levels (Fig. 3) , but no significant elevation in ROS levels was observed one or five hours after stimulation (Fig. 3) . We therefore tested the possibility that TTF could protect neuronal cells from Aβ 25-35 -induced cell death by inhibiting the Aβ 25-35 -induced production of ROS. Cells were treated with various concentrations of TTF, simultaneously with application of Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . Changes in intracellular levels of ROS were detected with the ROS indicator DCF-DA, and ROS formation was determined by examining fluorescence after 20 h. Our results show that treatment with TTF at a concentration of 25 nM -similar to that used to protect cells from Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] -induced cell death -inhibited the intracellular levels of Aβ 25-35 -induced ROS by 60% (Table 1) .
Inhibitory effect of TTF on Aβ-induced phosphorylation of SAPK/JNK and ERK 1/2 in N2a cells
Mitogen-activated protein kinases (MAPKs) -a family of serine/threonine protein kinases -which initiate many cellular responses to external stress signals, were shown to be modulated by flavonoids [12, 17] . Enhanced activation of SAPK/JNK and ERK 1/2, which belong to the MAPK cascade, was observed in AD-affected brains [18] [19] [20] . Moreover, Aβ has been reported to stimulate SAPK/JNK and ERK 1/2 [21] [22] [23] [24] . Therefore, we determined the effect of TTF on Aβ 25-35 -induced phosphorylation of SAPK/JNK and ERK 1/2.
As can be seen in (Figs 4a and b, respectively) . The total amounts of these proteins in the cells were not affected by TTF. It should be noted that TTF was more effective in inhibiting phosphorylation of ERK 1/2 than that of SAPK/JNK: at 3 nM it inhibited induced phosphorylation of ERK 1/2 by 84%, whereas at this concentration it inhibited that of SAPK/JNK by only 26%. These results suggest that inhibition of Aβ-induced phosphorylation of SAPK/JNK and ERK 1/2 is part of the mechanism by which TTF protects cells against Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] toxicity.
Discussion
In the present study we showed, for the first time, that TTF, a natural flavonoid that we isolated from A. fragrantissima [14] , could protect neuronal cells against Aβ-induced cell death, and that it inhibited phosphorylation of MAP kinases and attenuated the intracellular accumulation of ROS following treatment with Aβ. To the best of our knowledge, this is the first study that investigated the effects of TTF on neuronal cells and on Aβ-induced cytotoxicity.
Drugs currently used for treating AD improve patients' functions symptomatically, but do not modify the disease mechanism; thus, development of new and more effective drugs is required. Herbs and medicinal plants have been demonstrated in animal and cellular models to exhibit various interventions against multiple targets related to AD, including anti-cholinesterase activity, anti-amyloid, anti-oxidant and anti-inflammatory, and therefore might affect disease progression [25] [26] [27] ; thus, they might affect disease mechanisms. Nutraceuticals that can protect neuronal cells from Aβ toxicity and oxidative stress are potential candidates for the treatment of Alzheimer's disease. It previously has been suggested that new strategies based on memantine combined with antioxidants, could provide a multitargeted therapy to enhance neuronal protection and prevent disease progression [28] . The antioxidant activities of TTF demonstrated in neuronal cells in the present study, and in astrocytes in our previous study [14] indicate that TTF is a potential component of combined therapies.
Most flavonoids are metabolized in the gastrointestinal tract and liver and are absorbed into the bloodstream; and some of them were shown to cross the blood/brain barrier (BBB) into the central nervous system [29] [30] [31] [32] [33] . Flavonoids were shown to have neuroprotective effects, to impact neuronal function, to modulate neurotransmission, and to improve synaptic plasticity and cognition. Moreover, although astrocytes were proposed to mediate the actions of flavonoids in the brain, little is known about their cellular targets [32] . Aβ-induced neurotoxicity might be mediated through several Aβ-binding proteins that were identified on neuron plasma membranes. [34] . Accordingly, TTF might manifest its protective effects by antagonizing these receptors. Our results that relate to inhibition of MAPK are compatible with other findings that showed flavonoids to modulate MAP-kinase signaling, or to directly bind to some protein kinases [35, 36] .
Conclusions
Taken together, our findings suggest that by interfering with Aβ-induced signaling events and inhibiting elevation of intracellular ROS, TTF protects cells against Aβ-toxicity. In light of our previous results in astrocytes and our present results in neuronal cells, as well as the results of oral safety studies of extracts prepared from A. fragrantissima [37] , further studies should be conducted, to substantiate the potential of TTF for therapeutic treatment of AD. were determined with specific ELISA kits. The levels of each of the phosphorylated proteins were normalized to the levels of the total amount of the related proteins, and are presented as means ± SEM of two experiments (n = 4) for SAPK/JNK, and of three experiments (n = 6) for ERK 1/2. **p < 0.01, ***p < 0.001, for comparison with cells that were treated with Aβ only
